{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:08:06Z","timestamp":1775869686670,"version":"3.50.1"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01EY027827"],"award-info":[{"award-number":["R01EY027827"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30-EY001765"],"award-info":[{"award-number":["P30-EY001765"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.nano.2019.01.001","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T01:42:51Z","timestamp":1548034971000},"page":"119-123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization"],"prefix":"10.1016","volume":"17","author":[{"given":"Bing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yating","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas W.","family":"Lamb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda J.","family":"Suarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuo","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vineet","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles G.","family":"Eberhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Ensign","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter J.","family":"Stark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Hanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingguo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2019.01.001_bb0005","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/ICO.0b013e318201405a","article-title":"Treatments for corneal neovascularization: a review","volume":"30","author":"Gupta","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.nano.2019.01.001_bb0010","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2019.01.001_bb0015","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.survophthal.2008.08.002","article-title":"Adherence and persistence with glaucoma therapy","volume":"53","author":"Schwartz","year":"2008","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.nano.2019.01.001_bb0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2015.01.009","article-title":"Corticosteroid-loaded biodegradable nanoparticles for prevention of corneal allograft rejection in rats","volume":"201","author":"Pan","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2019.01.001_bb0025","unstructured":"McDonnell PJ, Khan YA, Lai SK, Kashiwabuchi RT, Behrens A and Hanes JS, Sustained Delivery of Therapeutic Agents to an Eye Compartment, U.S. Patent No. 8889193 B2, Issued November 18, 2014."},{"key":"10.1016\/j.nano.2019.01.001_bb0030","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1167\/iovs.11-8499","article-title":"Anti-angiogenic effect of KR-31831 on corneal and choroidal neovascularization in rat models","volume":"53","author":"Kim","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.nano.2019.01.001_bb0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/archopht.1977.04450020112019","article-title":"Periocular injection of corticosteroids-experimental evaluation of its role in treatment of corneal inflammation","volume":"95","author":"Leibowitz","year":"1977","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.nano.2019.01.001_bb0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/bjo.76.11.681","article-title":"Pharmacokinetics of ophthalmic corticosteroids","volume":"76","author":"McGhee","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.nano.2019.01.001_bb0045","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1021\/js9802594","article-title":"Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye","volume":"87","author":"Prausnitz","year":"1998","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nano.2019.01.001_bb0050","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0002-9394(99)00129-4","article-title":"High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection","volume":"128","author":"Weijtens","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.nano.2019.01.001_bb0055","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/archopht.1969.00990010790006","article-title":"Increased intraocular pressure following subconjunctival corticosteroid administration","volume":"81","author":"Kalina","year":"1969","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.nano.2019.01.001_bb0060","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1002\/anie.201006849","article-title":"Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus","volume":"50","author":"Yang","year":"2011","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.nano.2019.01.001_bb0065","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2009.04.001","article-title":"Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness","volume":"375","author":"Ishihara","year":"2009","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2019.01.001_bb0070","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11095-010-0159-x","article-title":"Biodegradable implants for sustained drug release in the eye","volume":"27","author":"Lee","year":"2010","journal-title":"Pharm Res"},{"key":"10.1016\/j.nano.2019.01.001_bb0075","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/ICO.0b013e31823f8b40","article-title":"Activated macrophages induce neovascularization through upregulation of MMP-9 and VEGF in rat corneas","volume":"31","author":"Li","year":"2012","journal-title":"Cornea"},{"key":"10.1016\/j.nano.2019.01.001_bb0080","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.nano.2019.01.001_bb0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcjo.2012.12.003","article-title":"Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization","volume":"48","author":"Ozdemir","year":"2013","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.nano.2019.01.001_bb0090","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1442-9071.2010.02252.x","article-title":"Inhibition of corneal neovascularization after alkali burn: comparison of different doses of bevacizumab in monotherapy or associated with dexamethasone","volume":"38","author":"Hoffart","year":"2010","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.nano.2019.01.001_bb0095","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","article-title":"Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and sunitinib (anti-VEGF and anti-PDGF) in an animal model","volume":"150","author":"P\u00e9rez-Santonja","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.nano.2019.01.001_bb0100","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1172\/JCI6870","article-title":"Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention","volume":"103","author":"Stetler-Stevenson","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nano.2019.01.001_bb0105","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1006\/exer.1999.0790","article-title":"Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization","volume":"70","author":"Kvanta","year":"2000","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.nano.2019.01.001_bb0110","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1155\/2014\/452685","article-title":"Inhibition of corneal neovascularization by topical and subconjunctival tigecycline","volume":"2014","author":"Goktas","year":"2014","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.nano.2019.01.001_bb0115","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1172\/JCI69774","article-title":"Ocular-specific ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma","volume":"124","author":"Zode","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nano.2019.01.001_bb0120","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1001\/archopht.1992.01080220054021","article-title":"The collaborative corneal transplantation studies (CCTS). Effectiveness of histocompatibility matching in high-risk corneal transplantation. The collaborative corneal transplantation studies research group","volume":"110","author":"Stark","year":"1992","journal-title":"Arch Ophthalmol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963419300127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963419300127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:09:44Z","timestamp":1761548984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963419300127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":24,"alternative-id":["S1549963419300127"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2019.01.001","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Controlled release of dexamethasone sodium phosphate with biodegradable nanoparticles for preventing experimental corneal neovascularization","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2019.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}